The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061
in the new oral formulation in the fasted state in healthy male and female volunteers. The
secondary objective of this study is to evaluate the safety and tolerability of BIIB061 in
the new formulation in this study population.